Lucintel’s latest market report analyzed that microbiome sequencing provides attractive opportunities in drug discovery, genetic screening, disease diagnosis research, and personalized medicine. The microbiome sequencing market is expected to grow at a CAGR of 17%-19%. In this market, sanger sequencing is the largest segment by sequencing technology, whereas pharmaceutical and biotechnology companies are largest by end user.
Download Brochure of this report by clicking on https://www.lucintel.com/microbiome-sequencing-market.aspx
Based on sequencing technology, the microbiome sequencing market is segmented into sanger sequencing, high-throughput sequencing (SBS, SBL, shotgun sequencing, TGS, RNA sequencing, WGS, and others), and third-generation sequencing. The sanger sequencing segment accounted for the largest share of the market in 2020 as it is preferred more by researchers because of higher accuracy than other technologies.
Browse in-depth TOC on “Microbiome Sequencing Market”
XX – Tables
XX – Figures
The microbiome sequencing market is marked by the presence of several big and small players. Some of the prominent players offering microbiome sequencing include Thermo Fisher Scientific, Illumina, Qiagen, Molzym, Novogene, Allele, Baseclear, BGI, Biolog, and Biomathematica.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link firstname.lastname@example.org.
Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.